{"nctId":"NCT01078909","briefTitle":"Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation","startDateStruct":{"date":"2011-10"},"conditions":["Cardiovascular Disease","Inflammation"],"count":125,"armGroups":[{"label":"300mg Fish Oil (EPA + DHA) Supplement","type":"EXPERIMENTAL","interventionNames":["Biological: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)"]},{"label":"600mg Fish Oil (EPA+DHA) Supplement","type":"EXPERIMENTAL","interventionNames":["Biological: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)"]},{"label":"900mg Fish Oil (EPA + DHA) Supplement","type":"EXPERIMENTAL","interventionNames":["Biological: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)"]},{"label":"1800mg Fish Oil (EPA + DHA) Supplement","type":"EXPERIMENTAL","interventionNames":["Biological: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)"]}],"interventions":[{"name":"Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)","otherNames":["Omega-3 Fatty Acids","Fish Oil"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy men and non-pregnant/lactating women between the ages of 20 and 45\n* BMI \\>19.9 and \\<30.0\n* Able to give written informed consent and willing to comply with all study- related procedures.\n\nExclusion Criteria:\n\n* Previous history of heart disease or diabetes\n* Renal Insufficiency\n* Chronic anti-inflammatory use\n* Systolic blood pressure \\< 90\n* Individuals currently using tobacco products or have done so in the previous 30 days\n* Individuals taking Omega-3 fatty acid supplements or their usual intake of fish is greater than 3-4 servings per month.","healthyVolunteers":true,"sex":"ALL","minimumAge":"20 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Concentrations of Inflammatory Markers (TNF-alpha and IL-6) Following 5 Months of Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"1.4","spread":null},{"groupId":"OG003","value":"1.5","spread":null},{"groupId":"OG004","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0.9","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Concentrations of CRP Following 5 Months of Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.6","spread":null},{"groupId":"OG003","value":"0.6","spread":null},{"groupId":"OG004","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Lipid Mediators","description":"0 Participants Analyzed; Lipid mediators were unable to be detected therefore there are no data to report.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":[]}}}